Harvard Bioscience (HBIO)
(Delayed Data from NSDQ)
$2.91 USD
-0.21 (-6.73%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $2.94 +0.03 (1.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HBIO 2.91 -0.21(-6.73%)
Will HBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HBIO
Bruker (BRKR) Q2 Earnings Meet Estimates
Mettler-Toledo (MTD) Surpasses Q2 Earnings and Revenue Estimates
HBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harvard Bioscience (HBIO) Q1 Earnings Match Estimates
Bruker (BRKR) Q1 Earnings Beat Estimates
Watch These 5 Technology Stocks for Q1 Earnings: Beat or Miss?
Other News for HBIO
HBIO Stock Earnings: Harvard Bioscience Misses Revenue for Q2 2024
Harvard Bioscience: Q2 Earnings Snapshot
Harvard Bioscience Announces Second Quarter 2024 Financial Results
Harvard Bioscience Non-GAAP EPS of $0.00 misses by $0.05, revenue of $23.1M misses by $3.3M
Harvard Bioscience reports Q2 adjusted EPS 0c vs. 4c last year